A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method

Atsushi Saito; Mitsuo Sakamoto; Akira Saito; Mitsuhide Ohmichi; Yohmei Hiraga; Kenjiro Kikuchi; Yoshinobu Ohsaki; Nobuhiro Sasaki; Hiroyuki Matsumoto; Toshihiro Suda; Moriyasu Tsuzino; Yuichi Hirai; Hiroshi Inoue; Masami Yoshida; Takashi Mouri; Hitoshi Kobayashi; Shinichi Chiba; Takashi Ito; Katsuyoshi Moriya; Takeshi Bando; Kenichi Takeuchi; Yukio Tanifuji; Kunio Shirato; Yasuo Tanno; Makoto Takahashi; Masahiro Sakamoto; Toshihiro Nukiwa; Akira Watanabe; Kazuo Sato; Mitsunobu Homma; Nobuo Ito; Kenji Yanase; Kunio Dote; Akira Ohishi; Kiyoshi Fukuda; Masataka Katsu; Osamu Sakai; Kohya Shiba; Hiroyuki Kobayashi; Susumu Sakayori; Hiroshi Miura; Hidehiro Watanabe; Kaoru Shimada; Shinichi Oka; Hirotaka Sugiyama; Takashi Inamatsu; Yasuyuki Sano; Yasuo Arai; Mamoru Otomo; Matsunobu Sukou; Hideo Kobayashi; Susumu Sikata; Harumi Shishido; Keiko Tsuchihashi; Koichiro Nakata; Eiyasu Tsuboi; Tatsuo Nakatani; Yoshitaka Nakamori; Izumi Hayashi; Masaru Koyama; Takao Okubo; Kenji Tani; Tamotsu Kaneko; Masanori Matsumura; Shigeto Takagi; Hideyuki Hasegawa; Hiroyuki Numata; Tsutomu Fukuda; Shoichiro Irimajiri; Yasuo Matsuoka; Mitsuo Obana; Fumio Matsumoto; Iwao Sakurai; Shigeki Odagiri; Kenichi Takahashi; Kaneo Suzuki; Masaaki Arakawa; Koichi Wada; Fumihide Iwata; Yoshinori Shimazu; Hiroyuki Sega; Hiroki Tsukada; Takashi Kawashima; Nobuki Aoki; Yasutoshi Suzuki; Osamu Sekine; Atsuhiko Sato; Yutaka Nakano; Ryoji Tamura; Hideki Suganuma; Masahiro Shirai; Sumio Kawakatsu; Takayoshi Watanabe; Jinichiro Akiyama; Takeshi Yagi; Katsutaka Torikai; Syusaku Fukaya; Akiei Mizutani; Toshihiko Takeuchi; Yasuo Yamada; Hidekazu Hanaki; Makoto Kawakami; Yoshimitsu Hayashi; Tomoyuki Tashiro; Ryuji Nomura; Kenzo Takagi; Yasunobu Noda; Hideo Gonda; Hiroyuki Taniguchi; Saburo Izumi; Fumiyuki Kuze; Akio Niimi; Yosiro Mochizuki; Yasuji Nakahara; Tetsuji Kawamura; Tadamitsu Kishimoto; Yoshiro Tanio; Tsuyoshi Igarashi; Kiyoshi Komuta; Masami Ito; Takeshi Okumoto; Masahide Mori; Kiyoshi Jozaki; Seibun Yonezu; Fumio Miki; Kazuya Higashino; Takashi Nakano; Mitsutomi Miyake; Toshihiko Nishian; Shinichiro Iida; Sayaka Yamamoto; Akio Maebo; Takahiko Yoshimoto; Takashi Sonoda; Masakiyo Nakagawa; Masataka Hirabayashi; Naoki Togawa; Masao Yoshida; Yoshitaka Kawai; Rinzo Soejima; Niro Okimoto; Toshiharu Matsushima; Makoto Kimura; Michio Yamakido; Shinichi Ishioka; Masao Kuwahara; Nobuhiro Mochizuki; Teruomi Miyazawa; Masao Doi; Kenichi Arita; Kazuhiro Daido; Tsuyoshi Ejima; Yoshiro Sawae; Koji Takaki; Minoru Yoshida; Takamichi Aritomi; Kotaro Oizumi; Yoichiro Ichikawa; Tsuneaki Shiraishi; Yoshiyuki Mitsutake; Fumio Tanaka; Takaoki Ohtsuka; Masashi Kawahara; Shinzo Kawaguchi; Tomotaka Kawayama; Yoshihiro Sato; Yoshiaki Honda; Tsuneo Ishibashi; Masahiro Takamoto; Akira Kajiki; Yasuko Harada; Masayuki Ando; Moritaka Suga; Katsumasa Tokunaga; Kiyoshi Shima; Shinobu Takenaka; Kohei Hara; Shigeru Kohno; Mitsuo Kaku; Nobuhiro Koga; Yuichi Inoue; Yuko Yamasita; Shingo Sakata; Takeshi Fujii; Kenji Irifune; Kazunori Shimoguchi; Yoshitsugu Miyazaki; Keizo Matsumoto; Tsuyoshi Nagatake; Masakazu Takasugi; Mikio Fujishita; Masaru Nasu; Tohru Yamasaki; Yoichiro Goto; Kaoru Nakama; Soichi Inoue; Shigeru Matsukura; Hideo Mashimoto; Hiroshi Mukae; Atsushi Saito; Hiroshi Fukuhara; Tominori Oyakawa; Koichi Deguchi; Mitsuyoshi Nakashima

A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method

Atsushi Saito, Mitsuo Sakamoto, Akira Saito, Mitsuhide Ohmichi, Yohmei Hiraga, Kenjiro Kikuchi, Yoshinobu Ohsaki, Nobuhiro Sasaki, Hiroyuki Matsumoto, Toshihiro Suda, Moriyasu Tsuzino, Yuichi Hirai, Hiroshi Inoue, Masami Yoshida, Takashi Mouri, Hitoshi Kobayashi, Shinichi Chiba, Takashi Ito, Katsuyoshi Moriya, Takeshi BandoKenichi Takeuchi, Yukio Tanifuji, Kunio Shirato, Yasuo Tanno, Makoto Takahashi, Masahiro Sakamoto, Toshihiro Nukiwa, Akira Watanabe, Kazuo Sato, Mitsunobu Homma, Nobuo Ito, Kenji Yanase, Kunio Dote, Akira Ohishi, Kiyoshi Fukuda, Masataka Katsu, Osamu Sakai, Kohya Shiba, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Hidehiro Watanabe, Kaoru Shimada, Shinichi Oka, Hirotaka Sugiyama, Takashi Inamatsu, Yasuyuki Sano, Yasuo Arai, Mamoru Otomo, Matsunobu Sukou, Hideo Kobayashi, Susumu Sikata, Harumi Shishido, Keiko Tsuchihashi, Koichiro Nakata, Eiyasu Tsuboi, Tatsuo Nakatani, Yoshitaka Nakamori, Izumi Hayashi, Masaru Koyama, Takao Okubo, Kenji Tani, Tamotsu Kaneko, Masanori Matsumura, Shigeto Takagi, Hideyuki Hasegawa, Hiroyuki Numata, Tsutomu Fukuda, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Iwao Sakurai, Shigeki Odagiri, Kenichi Takahashi, Kaneo Suzuki, Masaaki Arakawa, Koichi Wada, Fumihide Iwata, Yoshinori Shimazu, Hiroyuki Sega, Hiroki Tsukada, Takashi Kawashima, Nobuki Aoki, Yasutoshi Suzuki, Osamu Sekine, Atsuhiko Sato, Yutaka Nakano, Ryoji Tamura, Hideki Suganuma, Masahiro Shirai, Sumio Kawakatsu, Takayoshi Watanabe, Jinichiro Akiyama, Takeshi Yagi, Katsutaka Torikai, Syusaku Fukaya, Akiei Mizutani, Toshihiko Takeuchi, Yasuo Yamada, Hidekazu Hanaki, Makoto Kawakami, Yoshimitsu Hayashi, Tomoyuki Tashiro, Ryuji Nomura, Kenzo Takagi, Yasunobu Noda, Hideo Gonda, Hiroyuki Taniguchi, Saburo Izumi, Fumiyuki Kuze, Akio Niimi, Yosiro Mochizuki, Yasuji Nakahara, Tetsuji Kawamura, Tadamitsu Kishimoto, Yoshiro Tanio, Tsuyoshi Igarashi, Kiyoshi Komuta, Masami Ito, Takeshi Okumoto, Masahide Mori, Kiyoshi Jozaki, Seibun Yonezu, Fumio Miki, Kazuya Higashino, Takashi Nakano, Mitsutomi Miyake, Toshihiko Nishian, Shinichiro Iida, Sayaka Yamamoto, Akio Maebo, Takahiko Yoshimoto, Takashi Sonoda, Masakiyo Nakagawa, Masataka Hirabayashi, Naoki Togawa, Masao Yoshida, Yoshitaka Kawai, Rinzo Soejima, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Shinichi Ishioka, Masao Kuwahara, Nobuhiro Mochizuki, Teruomi Miyazawa, Masao Doi, Kenichi Arita, Kazuhiro Daido, Tsuyoshi Ejima, Yoshiro Sawae, Koji Takaki, Minoru Yoshida, Takamichi Aritomi, Kotaro Oizumi, Yoichiro Ichikawa, Tsuneaki Shiraishi, Yoshiyuki Mitsutake, Fumio Tanaka, Takaoki Ohtsuka, Masashi Kawahara, Shinzo Kawaguchi, Tomotaka Kawayama, Yoshihiro Sato, Yoshiaki Honda, Tsuneo Ishibashi, Masahiro Takamoto, Akira Kajiki, Yasuko Harada, Masayuki Ando, Moritaka Suga, Katsumasa Tokunaga, Kiyoshi Shima, Shinobu Takenaka, Kohei Hara, Shigeru Kohno, Mitsuo Kaku, Nobuhiro Koga, Yuichi Inoue, Yuko Yamasita, Shingo Sakata, Takeshi Fujii, Kenji Irifune, Kazunori Shimoguchi, Yoshitsugu Miyazaki, Keizo Matsumoto, Tsuyoshi Nagatake, Masakazu Takasugi, Mikio Fujishita, Masaru Nasu, Tohru Yamasaki, Yoichiro Goto, Kaoru Nakama, Soichi Inoue, Shigeru Matsukura, Hideo Mashimoto, Hiroshi Mukae, Atsushi Saito, Hiroshi Fukuhara, Tominori Oyakawa, Koichi Deguchi, Mitsuyoshi Nakashima

Rheumatology

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.

Original language	English
Pages (from-to)	63-68
Number of pages	6
Journal	Japanese Journal of Antibiotics
Volume	49
Issue number	2
Publication status	Published - 02-1996

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

Cite this

Saito, A., Sakamoto, M., Saito, A., Ohmichi, M., Hiraga, Y., Kikuchi, K., Ohsaki, Y., Sasaki, N., Matsumoto, H., Suda, T., Tsuzino, M., Hirai, Y., Inoue, H., Yoshida, M., Mouri, T., Kobayashi, H., Chiba, S., Ito, T., Moriya, K., ... Nakashima, M. (1996). A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method. Japanese Journal of Antibiotics, 49(2), 63-68.

@article{05655acbcb244c14a2fd0fa98efeae78,

title = "A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method",

abstract = "To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.",

author = "Atsushi Saito and Mitsuo Sakamoto and Akira Saito and Mitsuhide Ohmichi and Yohmei Hiraga and Kenjiro Kikuchi and Yoshinobu Ohsaki and Nobuhiro Sasaki and Hiroyuki Matsumoto and Toshihiro Suda and Moriyasu Tsuzino and Yuichi Hirai and Hiroshi Inoue and Masami Yoshida and Takashi Mouri and Hitoshi Kobayashi and Shinichi Chiba and Takashi Ito and Katsuyoshi Moriya and Takeshi Bando and Kenichi Takeuchi and Yukio Tanifuji and Kunio Shirato and Yasuo Tanno and Makoto Takahashi and Masahiro Sakamoto and Toshihiro Nukiwa and Akira Watanabe and Kazuo Sato and Mitsunobu Homma and Nobuo Ito and Kenji Yanase and Kunio Dote and Akira Ohishi and Kiyoshi Fukuda and Masataka Katsu and Osamu Sakai and Kohya Shiba and Hiroyuki Kobayashi and Susumu Sakayori and Hiroshi Miura and Hidehiro Watanabe and Kaoru Shimada and Shinichi Oka and Hirotaka Sugiyama and Takashi Inamatsu and Yasuyuki Sano and Yasuo Arai and Mamoru Otomo and Matsunobu Sukou and Hideo Kobayashi and Susumu Sikata and Harumi Shishido and Keiko Tsuchihashi and Koichiro Nakata and Eiyasu Tsuboi and Tatsuo Nakatani and Yoshitaka Nakamori and Izumi Hayashi and Masaru Koyama and Takao Okubo and Kenji Tani and Tamotsu Kaneko and Masanori Matsumura and Shigeto Takagi and Hideyuki Hasegawa and Hiroyuki Numata and Tsutomu Fukuda and Shoichiro Irimajiri and Yasuo Matsuoka and Mitsuo Obana and Fumio Matsumoto and Iwao Sakurai and Shigeki Odagiri and Kenichi Takahashi and Kaneo Suzuki and Masaaki Arakawa and Koichi Wada and Fumihide Iwata and Yoshinori Shimazu and Hiroyuki Sega and Hiroki Tsukada and Takashi Kawashima and Nobuki Aoki and Yasutoshi Suzuki and Osamu Sekine and Atsuhiko Sato and Yutaka Nakano and Ryoji Tamura and Hideki Suganuma and Masahiro Shirai and Sumio Kawakatsu and Takayoshi Watanabe and Jinichiro Akiyama and Takeshi Yagi and Katsutaka Torikai and Syusaku Fukaya and Akiei Mizutani and Toshihiko Takeuchi and Yasuo Yamada and Hidekazu Hanaki and Makoto Kawakami and Yoshimitsu Hayashi and Tomoyuki Tashiro and Ryuji Nomura and Kenzo Takagi and Yasunobu Noda and Hideo Gonda and Hiroyuki Taniguchi and Saburo Izumi and Fumiyuki Kuze and Akio Niimi and Yosiro Mochizuki and Yasuji Nakahara and Tetsuji Kawamura and Tadamitsu Kishimoto and Yoshiro Tanio and Tsuyoshi Igarashi and Kiyoshi Komuta and Masami Ito and Takeshi Okumoto and Masahide Mori and Kiyoshi Jozaki and Seibun Yonezu and Fumio Miki and Kazuya Higashino and Takashi Nakano and Mitsutomi Miyake and Toshihiko Nishian and Shinichiro Iida and Sayaka Yamamoto and Akio Maebo and Takahiko Yoshimoto and Takashi Sonoda and Masakiyo Nakagawa and Masataka Hirabayashi and Naoki Togawa and Masao Yoshida and Yoshitaka Kawai and Rinzo Soejima and Niro Okimoto and Toshiharu Matsushima and Makoto Kimura and Michio Yamakido and Shinichi Ishioka and Masao Kuwahara and Nobuhiro Mochizuki and Teruomi Miyazawa and Masao Doi and Kenichi Arita and Kazuhiro Daido and Tsuyoshi Ejima and Yoshiro Sawae and Koji Takaki and Minoru Yoshida and Takamichi Aritomi and Kotaro Oizumi and Yoichiro Ichikawa and Tsuneaki Shiraishi and Yoshiyuki Mitsutake and Fumio Tanaka and Takaoki Ohtsuka and Masashi Kawahara and Shinzo Kawaguchi and Tomotaka Kawayama and Yoshihiro Sato and Yoshiaki Honda and Tsuneo Ishibashi and Masahiro Takamoto and Akira Kajiki and Yasuko Harada and Masayuki Ando and Moritaka Suga and Katsumasa Tokunaga and Kiyoshi Shima and Shinobu Takenaka and Kohei Hara and Shigeru Kohno and Mitsuo Kaku and Nobuhiro Koga and Yuichi Inoue and Yuko Yamasita and Shingo Sakata and Takeshi Fujii and Kenji Irifune and Kazunori Shimoguchi and Yoshitsugu Miyazaki and Keizo Matsumoto and Tsuyoshi Nagatake and Masakazu Takasugi and Mikio Fujishita and Masaru Nasu and Tohru Yamasaki and Yoichiro Goto and Kaoru Nakama and Soichi Inoue and Shigeru Matsukura and Hideo Mashimoto and Hiroshi Mukae and Atsushi Saito and Hiroshi Fukuhara and Tominori Oyakawa and Koichi Deguchi and Mitsuyoshi Nakashima",

year = "1996",

month = feb,

language = "English",

volume = "49",

pages = "63--68",

journal = "The Journal of antibiotics. Ser. B",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "2",

}

Saito, A, Sakamoto, M, Saito, A, Ohmichi, M, Hiraga, Y, Kikuchi, K, Ohsaki, Y, Sasaki, N, Matsumoto, H, Suda, T, Tsuzino, M, Hirai, Y, Inoue, H, Yoshida, M, Mouri, T, Kobayashi, H, Chiba, S, Ito, T, Moriya, K, Bando, T, Takeuchi, K, Tanifuji, Y, Shirato, K, Tanno, Y, Takahashi, M, Sakamoto, M, Nukiwa, T, Watanabe, A, Sato, K, Homma, M, Ito, N, Yanase, K, Dote, K, Ohishi, A, Fukuda, K, Katsu, M, Sakai, O, Shiba, K, Kobayashi, H, Sakayori, S, Miura, H, Watanabe, H, Shimada, K, Oka, S, Sugiyama, H, Inamatsu, T, Sano, Y, Arai, Y, Otomo, M, Sukou, M, Kobayashi, H, Sikata, S, Shishido, H, Tsuchihashi, K, Nakata, K, Tsuboi, E, Nakatani, T, Nakamori, Y, Hayashi, I, Koyama, M, Okubo, T, Tani, K, Kaneko, T, Matsumura, M, Takagi, S, Hasegawa, H, Numata, H, Fukuda, T, Irimajiri, S, Matsuoka, Y, Obana, M, Matsumoto, F, Sakurai, I, Odagiri, S, Takahashi, K, Suzuki, K, Arakawa, M, Wada, K, Iwata, F, Shimazu, Y, Sega, H, Tsukada, H, Kawashima, T, Aoki, N, Suzuki, Y, Sekine, O, Sato, A, Nakano, Y, Tamura, R, Suganuma, H, Shirai, M, Kawakatsu, S, Watanabe, T, Akiyama, J, Yagi, T, Torikai, K, Fukaya, S, Mizutani, A, Takeuchi, T, Yamada, Y, Hanaki, H, Kawakami, M, Hayashi, Y, Tashiro, T, Nomura, R, Takagi, K, Noda, Y, Gonda, H, Taniguchi, H, Izumi, S, Kuze, F, Niimi, A, Mochizuki, Y, Nakahara, Y, Kawamura, T, Kishimoto, T, Tanio, Y, Igarashi, T, Komuta, K, Ito, M, Okumoto, T, Mori, M, Jozaki, K, Yonezu, S, Miki, F, Higashino, K, Nakano, T, Miyake, M, Nishian, T, Iida, S, Yamamoto, S, Maebo, A, Yoshimoto, T, Sonoda, T, Nakagawa, M, Hirabayashi, M, Togawa, N, Yoshida, M, Kawai, Y, Soejima, R, Okimoto, N, Matsushima, T, Kimura, M, Yamakido, M, Ishioka, S, Kuwahara, M, Mochizuki, N, Miyazawa, T, Doi, M, Arita, K, Daido, K, Ejima, T, Sawae, Y, Takaki, K, Yoshida, M, Aritomi, T, Oizumi, K, Ichikawa, Y, Shiraishi, T, Mitsutake, Y, Tanaka, F, Ohtsuka, T, Kawahara, M, Kawaguchi, S, Kawayama, T, Sato, Y, Honda, Y, Ishibashi, T, Takamoto, M, Kajiki, A, Harada, Y, Ando, M, Suga, M, Tokunaga, K, Shima, K, Takenaka, S, Hara, K, Kohno, S, Kaku, M, Koga, N, Inoue, Y, Yamasita, Y, Sakata, S, Fujii, T, Irifune, K, Shimoguchi, K, Miyazaki, Y, Matsumoto, K, Nagatake, T, Takasugi, M, Fujishita, M, Nasu, M, Yamasaki, T, Goto, Y, Nakama, K, Inoue, S, Matsukura, S, Mashimoto, H, Mukae, H, Saito, A, Fukuhara, H, Oyakawa, T, Deguchi, K & Nakashima, M 1996, 'A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method', Japanese Journal of Antibiotics, vol. 49, no. 2, pp. 63-68.

TY - JOUR

T1 - A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method

AU - Saito, Atsushi

AU - Sakamoto, Mitsuo

AU - Saito, Akira

AU - Ohmichi, Mitsuhide

AU - Hiraga, Yohmei

AU - Kikuchi, Kenjiro

AU - Ohsaki, Yoshinobu

AU - Sasaki, Nobuhiro

AU - Matsumoto, Hiroyuki

AU - Suda, Toshihiro

AU - Tsuzino, Moriyasu

AU - Hirai, Yuichi

AU - Inoue, Hiroshi

AU - Yoshida, Masami

AU - Mouri, Takashi

AU - Kobayashi, Hitoshi

AU - Chiba, Shinichi

AU - Ito, Takashi

AU - Moriya, Katsuyoshi

AU - Bando, Takeshi

AU - Takeuchi, Kenichi

AU - Tanifuji, Yukio

AU - Shirato, Kunio

AU - Tanno, Yasuo

AU - Takahashi, Makoto

AU - Sakamoto, Masahiro

AU - Nukiwa, Toshihiro

AU - Watanabe, Akira

AU - Sato, Kazuo

AU - Homma, Mitsunobu

AU - Ito, Nobuo

AU - Yanase, Kenji

AU - Dote, Kunio

AU - Ohishi, Akira

AU - Fukuda, Kiyoshi

AU - Katsu, Masataka

AU - Sakai, Osamu

AU - Shiba, Kohya

AU - Kobayashi, Hiroyuki

AU - Sakayori, Susumu

AU - Miura, Hiroshi

AU - Watanabe, Hidehiro

AU - Shimada, Kaoru

AU - Oka, Shinichi

AU - Sugiyama, Hirotaka

AU - Inamatsu, Takashi

AU - Sano, Yasuyuki

AU - Arai, Yasuo

AU - Otomo, Mamoru

AU - Sukou, Matsunobu

AU - Kobayashi, Hideo

AU - Sikata, Susumu

AU - Shishido, Harumi

AU - Tsuchihashi, Keiko

AU - Nakata, Koichiro

AU - Tsuboi, Eiyasu

AU - Nakatani, Tatsuo

AU - Nakamori, Yoshitaka

AU - Hayashi, Izumi

AU - Koyama, Masaru

AU - Okubo, Takao

AU - Tani, Kenji

AU - Kaneko, Tamotsu

AU - Matsumura, Masanori

AU - Takagi, Shigeto

AU - Hasegawa, Hideyuki

AU - Numata, Hiroyuki

AU - Fukuda, Tsutomu

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Obana, Mitsuo

AU - Matsumoto, Fumio

AU - Sakurai, Iwao

AU - Odagiri, Shigeki

AU - Takahashi, Kenichi

AU - Suzuki, Kaneo

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Iwata, Fumihide

AU - Shimazu, Yoshinori

AU - Sega, Hiroyuki

AU - Tsukada, Hiroki

AU - Kawashima, Takashi

AU - Aoki, Nobuki

AU - Suzuki, Yasutoshi

AU - Sekine, Osamu

AU - Sato, Atsuhiko

AU - Nakano, Yutaka

AU - Tamura, Ryoji

AU - Suganuma, Hideki

AU - Shirai, Masahiro

AU - Kawakatsu, Sumio

AU - Watanabe, Takayoshi

AU - Akiyama, Jinichiro

AU - Yagi, Takeshi

AU - Torikai, Katsutaka

AU - Fukaya, Syusaku

AU - Mizutani, Akiei

AU - Takeuchi, Toshihiko

AU - Yamada, Yasuo

AU - Hanaki, Hidekazu

AU - Kawakami, Makoto

AU - Hayashi, Yoshimitsu

AU - Tashiro, Tomoyuki

AU - Nomura, Ryuji

AU - Takagi, Kenzo

AU - Noda, Yasunobu

AU - Gonda, Hideo

AU - Taniguchi, Hiroyuki

AU - Izumi, Saburo

AU - Kuze, Fumiyuki

AU - Niimi, Akio

AU - Mochizuki, Yosiro

AU - Nakahara, Yasuji

AU - Kawamura, Tetsuji

AU - Kishimoto, Tadamitsu

AU - Tanio, Yoshiro

AU - Igarashi, Tsuyoshi

AU - Komuta, Kiyoshi

AU - Ito, Masami

AU - Okumoto, Takeshi

AU - Mori, Masahide

AU - Jozaki, Kiyoshi

AU - Yonezu, Seibun

AU - Miki, Fumio

AU - Higashino, Kazuya

AU - Nakano, Takashi

AU - Miyake, Mitsutomi

AU - Nishian, Toshihiko

AU - Iida, Shinichiro

AU - Yamamoto, Sayaka

AU - Maebo, Akio

AU - Yoshimoto, Takahiko

AU - Sonoda, Takashi

AU - Nakagawa, Masakiyo

AU - Hirabayashi, Masataka

AU - Togawa, Naoki

AU - Yoshida, Masao

AU - Kawai, Yoshitaka

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Yamakido, Michio

AU - Ishioka, Shinichi

AU - Kuwahara, Masao

AU - Mochizuki, Nobuhiro

AU - Miyazawa, Teruomi

AU - Doi, Masao

AU - Arita, Kenichi

AU - Daido, Kazuhiro

AU - Ejima, Tsuyoshi

AU - Sawae, Yoshiro

AU - Takaki, Koji

AU - Yoshida, Minoru

AU - Aritomi, Takamichi

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Shiraishi, Tsuneaki

AU - Mitsutake, Yoshiyuki

AU - Tanaka, Fumio

AU - Ohtsuka, Takaoki

AU - Kawahara, Masashi

AU - Kawaguchi, Shinzo

AU - Kawayama, Tomotaka

AU - Sato, Yoshihiro

AU - Honda, Yoshiaki

AU - Ishibashi, Tsuneo

AU - Takamoto, Masahiro

AU - Kajiki, Akira

AU - Harada, Yasuko

AU - Ando, Masayuki

AU - Suga, Moritaka

AU - Tokunaga, Katsumasa

AU - Shima, Kiyoshi

AU - Takenaka, Shinobu

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Kaku, Mitsuo

AU - Koga, Nobuhiro

AU - Inoue, Yuichi

AU - Yamasita, Yuko

AU - Sakata, Shingo

AU - Fujii, Takeshi

AU - Irifune, Kenji

AU - Shimoguchi, Kazunori

AU - Miyazaki, Yoshitsugu

AU - Matsumoto, Keizo

AU - Nagatake, Tsuyoshi

AU - Takasugi, Masakazu

AU - Fujishita, Mikio

AU - Nasu, Masaru

AU - Yamasaki, Tohru

AU - Goto, Yoichiro

AU - Nakama, Kaoru

AU - Inoue, Soichi

AU - Matsukura, Shigeru

AU - Mashimoto, Hideo

AU - Mukae, Hiroshi

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Oyakawa, Tominori

AU - Deguchi, Koichi

AU - Nakashima, Mitsuyoshi

PY - 1996/2

Y1 - 1996/2

N2 - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.

AB - To objectively evaluate the efficacy, safety and usefulness of the newly developed penem oral antibiotic, ritipenem acoxil (RIPM-AC), against bacterial pneumonia, we conducted a multi-center double-blind comparative study using cefotiam hexetil (CTM-HE) as the control drug. Both RIPM-AC and CTM-HE were orally administered at 200 mg t.i.d. for 14 days, in principle. The results were as follows: The total number of patients enrolled in this trial was 208, of which 152 cases (RIPM-AC group: 73, CTM-HE group: 79) were evaluable for clinical efficacy. 1. The clinical efficacy rates (excellent + good) were 91.8% (67/73) in the RIPM-AC group and 94.9% (75/79) in the CTM-HE group. There was no significant difference between the two groups, and the clinical equivalency of RIPM-AC to CTM-HE was demonstrated. 2. In the patients enrolled in the evaluation of clinical efficacy, the eradication rates of the causative organisms were 84.6% (22/26) in the RIPM-AC group and 91.7% (22/24) in the CTM-HE group, with no significant difference between the two groups. 3. Side effects were noted in 9 cases (9.6%) of the RIPM-AC group and 5 cases (4.9%) of the CTM-HE group. Abnormal laboratory test findings were observed in 23 cases (26.7%) of the RIPM-AC group and 15 cases (15.6%) of the CTM-HE group. There were no significant differences between the two groups in the incidence of side effects nor of abnormal laboratory test findings. In the safety evaluation, RIPM-AC was judged to be safe in 64 cases (68.1%) and CTM-HE in 82 cases (80.4%), with no significant difference. 4. The usefulness rates (markedly useful + useful) were 86.5% (64/74) in the RIPM-AC group and 92.5% (74/80) in the CTM-HE group. There was no significant difference between the two groups. Since RIPM-AC showed clinical efficacy similar to those of CTM-HE and posed no particular safety problems, it is expected to be a useful antibiotic for the treatment of bacterial pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=29344459609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344459609&partnerID=8YFLogxK

M3 - Review article

C2 - 8721077

AN - SCOPUS:29344459609

VL - 49

SP - 63

EP - 68

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 2

ER -

A comparative study on the efficacies of ritipenem acoxil and cefotiam hexetil in bacterial pneumonia by the double-blind method

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this